EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Effects of a Prolonged-Release Protein Substitute on 24-h Phenylalanine and Tyrosine Profiles in Phenylketonuria: A Randomized Crossover Study

Valentina Rovelli iD, Graziella Cefalo iD, Alice Re Dionigi iD, Annalisa Finizii, Sabrina Paci, Juri Zuvadelli, Giuseppe Banderali

Nutrients · 21.08.2026 · 18 (16) · 2738

DOI: 10.3390/nu18162738 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Nutrients, online erschienen am 21.08.2026. Verfasst von Valentina Rovelli und 6 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Department of Pediatrics, University of Milan, ASST Santi Paolo e Carlo, San Paolo Hospital, 20100 Milan, Italy. Hauptthemen laut MEDLINE: Phenylketonurias, Phenylalanine, Tyrosine, Dietary Proteins. Die Arbeit nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Applied Pharma Research (Switzerland), APR Applied Pharma Research SA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Achieving optimal metabolic control in phenylketonuria (PKU) remains challenging, particularly in adolescents and adults. Conventional free amino acid–based protein substitutes are absorbed rapidly, whereas prolonged-release formulations are designed to provide a more gradual amino acid release profile. Whether this translates into more favorable 24 h Phe and Tyr profiles and improved short-term biochemical parameters of metabolic control remains uncertain. This study evaluated whether a prolonged-release amino acid–based protein substitute (PR-AA) could improve 24 h metabolic control compared with standard protein substitutes.

Methods

This randomized, controlled, open-label crossover study included adolescents and adults with PKU aged ≥16 years. Participants received either conventional protein substitutes (standard of care; SC) or PR-AA three times daily for two consecutive days, followed by crossover to the alternate treatment. Blood spot samples were collected at five time points over 24 h on the second day of each treatment period. The primary outcome was the 24 h blood Phe profile. Secondary outcomes included blood Tyr, Phe/Tyr ratio, and exploratory assessment of branched-chain amino acids (BCAAs).

Results

Twenty-one patients were enrolled, of whom 16 were included in the intention-to-treat analysis and 12 in the per-protocol analysis. PR-AA treatment resulted in significantly lower mean blood Phe levels over 24 h compared with SC (522 ± 194 vs. 561 ± 165 µmol/L; p = 0.0009), corresponding to a reduction of approximately 6–7%. The effect was consistently observed throughout the 24-h assessment period, particularly during the early morning, and became detectable after only two days of treatment. PR-AA was also associated with significantly higher blood Tyr levels (approximately +18–20%; p < 0.05) and a lower Phe/Tyr ratio (approximately −20%; p < 0.001) compared with SC. Exploratory analyses demonstrated modestly lower and more stable BCAA profiles with PR-AA. No significant carryover effects or treatment-related safety concerns were observed.

Conclusions

Short-term treatment with a prolonged-release protein substitute was associated with modest but consistent improvements in short-term biochemical parameters of metabolic control in adolescents and adults with PKU, including lower blood Phe and higher Tyr levels, resulting in a reduced Phe/Tyr ratio. These findings suggest that optimizing amino acid delivery kinetics may represent a promising strategy to improve short-term metabolic control in PKU. Given the preliminary nature of these findings and the limited number of participants who completed the study protocol, larger studies with longer follow-up, including direct clinical and neurocognitive outcomes and formal variability metrics, are needed to determine the clinical relevance of these biochemical effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PhenylketonuriasPhenylalanineTyrosineDietary ProteinsHumansCross-Over StudiesAdolescentFemaleMaleAdultDelayed-Action PreparationsYoung Adult

Stichwörter der Autor:innen

blood phenylalaninemetabolic controlphenylalanine/tyrosine ratiophenylketonuria (PKU)prolonged-release amino acidsprolonged-release protein substitute

Substanzen

PhenylalanineTyrosineDelayed-Action PreparationsDietary Proteins

Autor:innen und Institutionen

  • Clinical Department of Pediatrics, University of Milan, ASST Santi Paolo e Carlo, San Paolo Hospital, 20100 Milan, Italy.

ORCID-Profile: Valentina Rovelli, Graziella Cefalo, Alice Re Dionigi

Förderung

  • Applied Pharma Research (Switzerland)
  • APR Applied Pharma Research SA

Zitieren

APA

Rovelli, V., Cefalo, G., Dionigi, A. R., Finizii, A., Paci, S., Zuvadelli, J., & Banderali, G. (2026). Effects of a Prolonged-Release Protein Substitute on 24-h Phenylalanine and Tyrosine Profiles in Phenylketonuria: A Randomized Crossover Study. Nutrients, 18(16), 2738. https://doi.org/10.3390/nu18162738

Vancouver

Rovelli V, Cefalo G, Dionigi AR, Finizii A, Paci S, Zuvadelli J, et al. Effects of a Prolonged-Release Protein Substitute on 24-h Phenylalanine and Tyrosine Profiles in Phenylketonuria: A Randomized Crossover Study. Nutrients. 2026;18(16):2738. doi:10.3390/nu18162738

BibTeX
@article{Rovelli2026,
  author = {Rovelli, Valentina and Cefalo, Graziella and Dionigi, Alice Re and Finizii, Annalisa and Paci, Sabrina and Zuvadelli, Juri and Banderali, Giuseppe},
  title = {Effects of a Prolonged-Release Protein Substitute on 24-h Phenylalanine and Tyrosine Profiles in Phenylketonuria: A Randomized Crossover Study},
  journal = {Nutrients},
  year = {2026},
  volume = {18},
  number = {16},
  pages = {2738},
  doi = {10.3390/nu18162738}
}
Kostenlos starten →